Impact of a new coronavirus infection on the clinical course of immunoinflammatory rheumatic diseases

Abstract

BACKGROUND: The COVID-19 pandemic poses a particular threat to patients suffering from immunoinflammatory rheumatic diseases. New coronavirus infection has been found to be accompanied by the development of a wide range of extrapulmonary clinical and laboratory manifestations, which are characteristic of a number of immunoinflammatory rheumatic diseases.

AIM: To evaluate the features of the clinical course of immunoinflammatory rheumatic diseases in patients who underwent new coronavirus infection.

MATERIALS AND METHODS: The clinical course of immunoinflammatory rheumatic diseases was analyzed in 324 patients who underwent new coronavirus infection from March 2020 to February 2021 and were treated at the Clinical Rheumatology Hospital No. 25, Saint Petersburg, for exacerbation of the underlying disease.

RESULTS: Analysis showed that the risk factors for severe new coronavirus infection in patients with immunoinflammatory rheumatic diseases were: age over 60, comorbidities, use of prednisolone in a dose greater than 12,5 mg, and ESR values ≥40 mm/hour before the development of new coronavirus infection. There was no effect of immunosuppressive and biological therapy on the severity of the course of viral infection. There was no effect of immunosuppressive therapy and biological therapy on the severity of the course of viral infection in patients with immunoinflammatory rheumatic diseases. The development of the postinfectious syndrome was observed in ¹/₄ of patients, which was characterized by the formation of postinfectious arthritis in 3,6% of patients, transformation of undifferentiated arthritis into various rheumatic diseases in 49% of patients (more often into early rheumatoid arthritis), as well as exacerbation of the underlying disease in 83,4% of patients with an advanced stage of rheumatoid arthritis. In patients with mixed connective tissue disease, there was a significant increase in immunologic activity due to antinuclear factor (up to a maximum of 1:163 840). Clinical cases of the development of arthritis associated with viral infection and the debut of rheumatoid arthritis after an new coronavirus infection are presented.

CONCLUSIONS: New coronavirus infection in the cohort of patients with immunoinflammatory rheumatic diseases observed in the Clinical Rheumatology Hospital No. 25, Saint Petersburg, proceeded in the variant of medium severity in half of patients, initiated the development of lung lesions in 68,6% of patients, arthritis associated with viral infection in 3,6% of patients, immunoinflammatory rheumatic diseases which transformed from undifferentiated arthritis in 49% of cases and exacerbation of the main disease in an overwhelming number of patients. Patients with immunoinflammatory rheumatic diseases have a high risk of adverse outcome of new coronavirus infection, especially in cases of unstable course of the disease or exacerbation of this group of diseases.

Keywords

new coronavirus infection / immunoinflammatory rheumatic diseases / undifferentiated arthritis / postcovid syndrome

References

[1] Nasonov EL. Coronavirus disease 2019 (COVID-19): A rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2): 123–132. (In Russ.). DOI: 10.14412/1995-4484-2020-123-132

[2] Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога // Научно-практическая ревматология. 2020. Т 58, № 2. С. 123–132. DOI: 10.14412/1995-4484-2020-123-132

[3] Halpert G, Shoenfeld Y. SARS-CoV-2, the autoimmune virus. Autoimmun Rev. 2020;19(12):102695. DOI: 10.1016/j.autrev.2020.102695

[4] Halpert G., Shoenfeld Y. SARS-CoV-2, the autoimmune virus // Autoimmun. Rev. 2020. Vol. 19, No. 12. P. 102695. DOI: 10.1016/j.autrev.2020.102695

[5] Remy KE, Mazer M, Striker DA, et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight. 2020;5(17):e140329. DOI: 10.1172/jci.insight.140329

[6] Remy K.E., Mazer M., Striker D.A. et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections // JCI Insight. 2020. Vol. 5, No. 17. P. e140329. DOI: 10.1172/jci.insight.140329

[7] Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Rheumatology Science and Practice. 2021;59(1):5–30. (In Russ.). DOI: 10.47360/1995-4484-2021-5-30

[8] Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет // Научно-практическая ревматология. 2021. Т. 59, № 1. С. 5–30. DOI: 10.47360/1995-4484-2021-5-30

[9] Song WC, FitzGerald GA. COVID-19, microangiopathy, hemostatic activation, and complement. J Clin Invest. 2020;130(8):3950–3953. DOI: 10.1172/JCI140183

[10] Song W.C., FitzGerald G.A. COVID-19, microangiopathy, hemostatic activation, and complement // J. Clin. Invest. 2020. Vol. 130, No. 8. P. 3950–3953. DOI: 10.1172/JCI140183

[11] Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Rheumatology Science and Practice. 2020;58(4):353–367. (In Russ.). DOI: 10.47360/1995-4484-2020-353-367

[12] Насонов Е.Л., Бекетова Т.В., Решетняк Т.М. и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета // Научно-практическая ревматология. 2020. Т. 58, № 4. С. 353–367. DOI: 10.47360/1995-4484-2020-353-367

[13] Osier F, Ting JPY, Fraser J, et al. The global response to the COVID-19 pandemic: how have immunology societies contributed? Nat Rev Immunol. 2020;20(10):594–602. DOI: 10.1038/s41577-020-00428-4

[14] Osier F., Ting J.P.Y., Fraser J. et al. The global response to the COVID-19 pandemic: how have immunology societies contributed? // Nat. Rev. Immunol. 2020. Vol. 20, No. 10. P. 594–602. DOI: 10.1038/s41577-020-00428-4

[15] Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020;ciaa478. DOI: 10.1093/cid/ciaa478

[16] Bhimraj A., Morgan R.L., Shumaker A.H. et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 // Clin. Infect. Dis. 2020. P. ciaa478. DOI: 10.1093/cid/ciaa478

[17] Robinson PC, Yazdany J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol. 2020;16(6):293–294. DOI: 10.1038/s41584-020-0418-0

[18] Robinson P.C., Yazdany J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic // Nat. Rev. Rheumatol. 2020. Vol. 16, No. 6. P. 293–294. DOI: 10.1038/s41584-020-0418-0

[19] Yazdany J. COVID-19 in rheumatic diseases: a research agenda. Arthritis Rheumatol. 2020;72(10):1596–1599. DOI: 10.1002/art.41447

[20] Yazdany J. COVID-19 in rheumatic diseases: a research agenda // Arthritis Rheumatol. 2020. Vol. 72, No. 10. P. 1596–1599. DOI: 10.1002/art.41447

[21] Weatherhead JE, Clark E, Vogel TP, et al. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum. J Clin Invest. 2020;130(12):6194–6197. DOI: 10.1172/JCI145301

[22] Weatherhead J.E., Clark E., Vogel T.P. et al. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum // J. Clin. Invest. 2020. Vol. 130, No. 12. P. 6194–6197. DOI: 10.1172/JCI145301

[23] Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271–272. DOI: 10.1038/s41577-020-0312-7

[24] Schett G., Sticherling M., Neurath M.F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? // Nat. Rev. Immunol. 2020. Vol. 20, No. 5. P. 271–272. DOI: 10.1038/s41577-020-0312-7

[25] Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465–470. DOI: 10.1038/s41584-020-0451-z

[26] Schett G., Manger B., Simon D., Caporali R. COVID-19 revisiting inflammatory pathways of arthritis // Nat. Rev. Rheumatol. 2020. Vol. 16, No. 8. P. 465–470. DOI: 10.1038/s41584-020-0451-z

RIGHTS & PERMISSIONS

Mazurov V.I., Belyaeva I.B., Sarantseva L.E., Chudinov A.L., Bashkinov R.A., Trofimov E.A., Smulskaya O.A., Inamova O.V., Petrova M.S., Melnikov E.S.